Todd C. Longsworth
Net Worth

Last updated:

What is Todd C. Longsworth net worth?

The estimated net worth of Mr. Todd C. Longsworth is at least $38,166,596 as of 8 Mar 2022. He owns shares worth $753,229 as insider, has earned $29,363,367 from insider trading and has received compensation worth at least $8,050,000 in NovoCure Limited.

What is the salary of Todd C. Longsworth?

Mr. Todd C. Longsworth salary is $1,150,000 per year as Gen. Counsel in NovoCure Limited.

How old is Todd C. Longsworth?

Mr. Todd C. Longsworth is 50 years old, born in 1975.

What stocks does Todd C. Longsworth currently own?

As insider, Mr. Todd C. Longsworth owns shares in one company:

Company Title Shares Price per share Total value
NovoCure Limited (NVCR) Gen. Counsel 62,462 $12.06 $753,229

What does NovoCure Limited do?

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR logo
NVCR
NovoCure Limited
$12.06

Todd C. Longsworth insider trading

NovoCure Limited

Mr. Todd C. Longsworth has made 22 insider trades between 2018-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,339 units of NVCR stock worth $163,964 on 8 Mar 2022.

The largest trade he's ever made was exercising 158,440 units of NVCR stock on 3 Sep 2019. As of 8 Mar 2022 he still owns at least 62,462 units of NVCR stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Ordinary Shares 2,339 $70.1 $163,964
Sale
Ordinary Shares 1,973 $70.41 $138,913
Sale
Ordinary Shares 1,094 $74.5 $81,501
Sale
Restricted Share Units 2,404 N/A N/A
Sale
Restricted Share Units 3,084 N/A N/A
Sale
Restricted Share Units 2,355 N/A N/A
Option
Restricted Stock Units 5,555 N/A N/A
Option
Ordinary Shares 5,555 N/A N/A
Sale
Ordinary Shares 63,814 $173.41 $11,066,050
Option
Ordinary Shares 36,396 N/A N/A
Sale
Ordinary Shares 63,814 $66.38 $4,235,973
Sale
Ordinary Shares 63,814 N/A N/A
Option
Options to Buy Ordinary Shares 36,396 N/A N/A
Sale
Restricted Share Units 2,499 N/A N/A
Sale
Ordinary Shares 2,643 N/A N/A
Option
Ordinary Shares 5,556 N/A N/A
Option
Restricted Stock Units 5,556 N/A N/A
Sale
Ordinary Shares 8,482 N/A N/A
Option
Restricted Stock Units 21,666 N/A N/A
Option
Ordinary Shares 21,666 N/A N/A
Option
Ordinary Shares 158,440 N/A N/A
Option
Options to Buy Ordinary Shares 146,808 N/A N/A
Sale
Ordinary Shares 152,809 $88.14 $13,468,127
Sale
Ordinary Shares 152,809 N/A N/A
Sale
Ordinary Shares 2,368 N/A N/A
Option
Restricted Stock Units 5,556 N/A N/A
Option
Ordinary Shares 5,556 N/A N/A
Sale
Ordinary Shares 9,325 N/A N/A
Option
Restricted Stock Units 21,667 N/A N/A
Option
Ordinary Shares 21,667 N/A N/A
Option
Options to Buy Ordinary Shares 11,874 N/A N/A
Sale
Ordinary Shares 11,874 N/A N/A
Option
Ordinary Shares 11,874 N/A N/A
Sale
Ordinary Shares 15,000 N/A N/A
Option
Ordinary Shares 15,000 N/A N/A
Option
Options to Buy Ordinary Shares 15,000 N/A N/A
Option
Ordinary Shares 15,000 N/A N/A
Sale
Ordinary Shares 15,000 N/A N/A
Option
Options to Buy Ordinary Shares 15,000 N/A N/A
Option
Options to Buy Ordinary Shares 15,000 N/A N/A
Sale
Ordinary Shares 15,000 N/A N/A
Option
Ordinary Shares 15,000 N/A N/A
Sale
Ordinary Shares 6,591 $19.83 $130,686
Option
Restricted Stock Units 21,667 N/A N/A
Option
Ordinary Shares 21,667 N/A N/A
Option
Ordinary Shares 11,630 $6.72 $78,154
Sale
Ordinary Shares 11,630 $6.72 $78,154
Option
Options to Buy Ordinary Shares 11,630 $6.72 $78,154

NovoCure Limited key executives

NovoCure Limited executives and other stock owners filed with the SEC: